Cobenfy (Xanomeline and Trospium): How This Schizophrenia Medicine Works and When Telehealth Is Enough

Last updated: August 25, 2026

Cobenfy is the brand name for a fixed-dose capsule that combines xanomeline and trospium chloride. The U.S. Food and Drug Administration approved it on September 26, 2024, for schizophrenia in adults. It is the first antipsychotic approved for that use that targets cholinergic (muscarinic) receptors rather than dopamine receptors, which had been the usual target for decades.

This page is education. It is not a diagnosis, a refill promise, or a claim that any plan will pay for Cobenfy. Coverage varies by plan. Verify benefits before you book. If you are in crisis, call or text 988.

See conditions Klarity treats or start with online anxiety treatment if worry, restlessness, or tension is the main problem you want to discuss.

TL;DR

• Cobenfy (xanomeline and trospium chloride) is an oral capsule for schizophrenia in adults. The FDA approved it on September 26, 2024, and granted the approval to Bristol-Myers Squibb. (FDA press announcement)
• It is the first approved schizophrenia antipsychotic that targets cholinergic receptors instead of dopamine receptors.
• Effectiveness came from two identical 5-week, randomized, double-blind, placebo-controlled multicenter studies in adults who met DSM-5 schizophrenia criteria. The primary measure was change in PANSS total score at week 5. People on Cobenfy had a meaningful reduction versus placebo in both studies.
• The label warns about urinary retention, faster heart rate, slower gut movement, and angioedema of the face and lips. There is also a risk of liver injury. Stop the drug and get care if you develop yellow skin or eyes, dark urine, or unexplained itching.
• Do not use Cobenfy if you have urinary retention, moderate or severe kidney or liver disease, gastric retention, untreated narrow-angle glaucoma, or a known allergy to the product. The FDA also says it is not recommended in mild hepatic impairment and should not be used in known hepatic impairment. The kidney clears much of the drug, so it is not recommended in moderate to severe renal impairment.
• Common side effects: nausea, indigestion, constipation, vomiting, high blood pressure, abdominal pain, diarrhea, tachycardia, dizziness, and GERD.
• Medicare behavioral telehealth in the home remains available on a permanent basis, with several other Medicare telehealth flexibilities extended through December 31, 2027 (HHS page last updated February 5, 2026). Klarity’s 2,000+ licensed providers can evaluate symptoms and discuss options. They cannot promise Cobenfy or any other specific drug.

On this page

• What is Cobenfy?
• How xanomeline and trospium work together
• What the FDA trials showed
• Who should not take it
• Side effects and liver or bladder warnings
• What telehealth can still do
• How Klarity fits
• FAQ

What is Cobenfy?

Cobenfy is a prescription capsule that contains two medicines: xanomeline and trospium chloride. DailyMed lists the product as coated-pellet capsules. The FDA indication is treatment of schizophrenia in adults. Development teams also used the research name KarXT. That name still shows up in older trial pages and news, but the U.S. brand is Cobenfy.

Schizophrenia can include hallucinations, trouble controlling thoughts, and suspicion of others. It can also include cognitive problems and trouble with social contact or motivation. The FDA notes that about 1% of Americans have the illness, that it is among the 15 leading causes of disability worldwide, and that people with schizophrenia face a higher risk of dying younger, with nearly 5% dying by suicide. Those are population facts, not a personal prognosis.

Cobenfy is not a first-generation phenothiazine and it is not a classic dopamine-blocking “typical” antipsychotic such as haloperidol or chlorpromazine. It is also not the same as second-generation options such as clozapine. A clinician matches the drug class to your history, labs, and other medicines.

How xanomeline and trospium work together

Xanomeline acts on muscarinic (cholinergic) receptors in the brain. Trospium is a peripherally restricted muscarinic antagonist. The pairing is meant to keep more of the central effect of xanomeline while blocking some of the peripheral cholinergic side effects. The FDA’s short description is that Cobenfy is the first approved schizophrenia antipsychotic that targets cholinergic receptors rather than dopamine receptors.

That new mechanism does not make the drug “side-effect free.” The same approval notice lists gut, bladder, heart-rate, liver, and allergy warnings. Take only the capsule and schedule your clinician writes. Do not crush or share leftover capsules, and do not buy unlabeled overseas “KarXT” powders.

What the FDA trials showed

The FDA based approval on two studies with the same design (Study 1 and Study 2). Both were 5-week, randomized, double-blind, placebo-controlled, multicenter trials in adults with DSM-5 schizophrenia. The primary efficacy measure was change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score at week 5. PANSS is a 30-item clinician-rated scale. In both studies, people assigned to Cobenfy had a meaningful drop in PANSS total score versus placebo.

Those were short, tightly controlled trials. They do not tell you how you will feel on week 6, how a specific plan will pay, or whether Cobenfy is a better personal fit than another antipsychotic. Your clinician still reviews prior trials, movement history, liver and kidney status, and bladder or glaucoma risk before any start.

Who should not take it

Per the FDA approval summary, Cobenfy should not be prescribed to people with:

• Urinary retention
• Moderate or severe kidney disease
• Moderate or severe liver disease
• Gastric retention
• Untreated narrow-angle glaucoma
• A history of hypersensitivity to Cobenfy or its components

The FDA also says Cobenfy is not recommended for patients with mild hepatic impairment and should not be used in patients with known hepatic impairment. Because the drug is substantially excreted by the kidney, it is not recommended in moderate to severe renal impairment.

Tell the clinician about prostate enlargement, trouble emptying the bladder, constipation or prior bowel obstruction, liver tests that were already high, kidney disease, glaucoma treatment, and every anticholinergic medicine you already take. Those details change risk even when the diagnosis is clearly schizophrenia.

Side effects and liver or bladder warnings

The most common side effects in the FDA summary are nausea, indigestion, constipation, vomiting, hypertension, abdominal pain, diarrhea, tachycardia, dizziness, and gastroesophageal reflux disease.

The prescribing information also warns that Cobenfy can cause urinary retention, increased heart rate, decreased gastric movement, or angioedema of the face and lips. The DailyMed label highlights urinary retention risk, including in geriatric patients and people who already have clinically significant bladder outlet problems.

There is a risk of liver damage. Stop Cobenfy and seek care if you notice yellowing of the skin or the whites of the eyes, dark urine, or unexplained itching. Those signs can point to substantial liver injury.

Angioedema (swelling of the face or lips), inability to pass urine, severe belly pain and vomiting, fainting, or a racing heartbeat that will not settle need urgent or emergency care, not a routine video follow-up.

This article does not reprint a milligram titration table. Strengths and schedules belong on the current DailyMed label and on your own prescription. If a dose change is on the table, the prescriber should also recheck bladder symptoms, heart rate, blood pressure, and whether liver labs are due.

What telehealth can still do

A video visit can review diagnosis questions, prior antipsychotic trials, side-effect history, and whether a muscarinic option is even in range. It can also plan labs, coordinate with a local draw site, and follow a stable course once someone is already on a tolerated regimen.

Telehealth is the wrong setting for new psychosis with danger to self or others, suspected liver injury, acute urinary retention, angioedema, or inability to keep yourself safe. Those need in-person or emergency care.

HHS states that Medicare patients can permanently receive behavioral health telehealth in the home. Several other Medicare telehealth flexibilities run through December 31, 2027 (page last updated February 5, 2026). That is federal policy language, not a guarantee that Cobenfy will be on your Part D or commercial formulary.

Browse conditions and next steps

How Klarity fits

Klarity Health connects adults with 2,000+ licensed U.S. providers. Many visits happen by video. A clinician can discuss schizophrenia and related symptoms and talk through medicines U.S. pharmacies actually stock. We do not promise that any plan will cover Cobenfy, that a prior authorization will go through, or that a video visit is enough for a first start.

Coverage varies by plan. Verify benefits before you book. Self-pay is also an option for many visit types.

See online anxiety treatment options · See conditions Klarity treats

FAQ

Is Cobenfy the same as KarXT?

KarXT was the research name for xanomeline plus trospium. The approved U.S. brand is Cobenfy.

Does Cobenfy block dopamine?

The FDA describes it as the first approved schizophrenia antipsychotic that targets cholinergic receptors rather than dopamine receptors. That is a different starting mechanism from older typical and many atypical antipsychotics.

Can I start Cobenfy online?

A telehealth clinician can take a history and decide whether any antipsychotic, including Cobenfy, is appropriate to discuss. New psychosis, liver or kidney disease, urinary retention, and glaucoma screening may still need in-person steps. Only a licensed prescriber can write the prescription.

Does insurance cover Cobenfy?

Coverage varies by plan and formulary. Many plans treat a newly approved brand as non-preferred or prior-authorization only. Verify benefits before you book. Klarity cannot guarantee coverage.

What if I cannot empty my bladder or my eyes turn yellow?

Stop the medicine and get urgent care. The FDA lists urinary retention and liver injury among the serious risks.

Disclaimer

This article is education, not medical advice, diagnosis, or a promise of treatment or insurance payment. Medication decisions belong to you and a licensed clinician. If you may harm yourself or someone else, call 911 or 988.

Sources: FDA approval announcement, September 26, 2024; DailyMed Cobenfy (xanomeline and trospium chloride); HHS telehealth policy updates.